At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 142 enrolled
Drug / intervention
Ixekizumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Dose-Ranging And Efficacy Study of LY2439821 (An Anti-IL-17 Antibody) In Patients With Moderate-To-Severe Psoriasis
In Brief
A Phase 2 clinical trial evaluating Ixekizumab and Placebo for Psoriasis. Completed, enrolled 142 participants across 34 sites in 2 countries.
Detailed Summary
The primary purpose for this study is to help answer the following research questions * The safety of ixekizumab (LY2439821) and any side effects that might be associated with it. * Whether ixekizumab can help participants with Psoriasis. * How much ixekizumab should be given to participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesDenmark, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2010
First PostedApr 2010
Primary CompletionJan 2011
Study CompletionJul 2016
TodayJul 2026
First PostedApr 21, 2010
Enrollment StartApr 1, 2010
Primary CompletionJan 1, 2011
Study CompletionJul 1, 2016
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 16.2 years ago
Interventions
Ixekizumabbiological
Administered subcutaneously
Placebodrug
Administered subcutaneously